Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × Aromatase Inhibitors × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 28 Neoplasm Metastasis 2 Luminal B/HER2-negative Breast Cancer 1 Hormone Receptor Positive Breast Carcinoma 1 Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1 Estrogen Receptor and/or Progesterone Receptor Positive 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Female 1 Arthralgia 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 8 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 Vinorelbine 2 Trastuzumab 2 Letrozole 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Moxifloxacin 1 Goserelin 1 Everolimus 1 Dasatinib 1 Cyclophosphamide 1 Cisplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04227327 2025-07-29

HERMIONE-7

University of Milano Bicocca

Phase 2 Terminated

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡